Status:
COMPLETED
Th1/Th2/Th17/TREG and TLRs Activation/KIR for COVID 19 Prediction of Outcome
Lead Sponsor:
Asociacion para el Estudio de las Enfermedades Infecciosas
Collaborating Sponsors:
Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal
Conditions:
Disease, Viral
Cytokine Release Syndrome
Eligibility:
All Genders
18-100 years
Brief Summary
To ascertain globally the changes in the cytokines involved and TLRs/KIR activation in patients admitted to the hospital with a COVID-19 diagnosis, and the changes after initiation of the different th...
Detailed Description
COVID-19 is a disease with an initial viral phase followed, usually at the 7th day, of an inflammatory state (cytokine storm) leading to respiratory distress, ICU admission and risk of death. Thus, se...
Eligibility Criteria
Inclusion
- Patients with a diagnosis of COVID-19 (PCR confirmed)
Exclusion
- No informed consent
- Presence of chronic therapy with immunomodulators, corticoids or antineoplastic agents.
Key Trial Info
Start Date :
May 22 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 10 2021
Estimated Enrollment :
106 Patients enrolled
Trial Details
Trial ID
NCT04403061
Start Date
May 22 2020
End Date
January 10 2021
Last Update
January 12 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hospital Ramon y Cajal
Madrid, Spain, 28034